You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Gastroenterology
2021: EoE Year in Review
Prof. Arjan Bredenoord and Dr. Evan Dellon highlight key scientific advances made in EoE in 2021 and their potential impacts on patient care
MD, MPH
Evan Dellon +1 more
Learning objectives
Understand the pathophysiology of EoE, including the role of the type 2 inflammatory cells (beyond eosinophils) and cytokines (including IL-4 and IL-13) in barrier dysfunction, immune cell trafficking, and esophageal remodeling
Learn about tools for multidimensional assessment, analysis of the impact of delayed diagnosis on disease progression, and the importance of long-term monitoring of EoE
Examine clinical data and ongoing clinical trials for approved and emerging targeted therapies for patients with EoE
Description
Global gastroenterology experts Arjan Bredenoord, MD, PhD, and Evan Dellon, MD, MPH, highlight key scientific advances made in EoE throughout 2021 and discuss their potential impacts on patient care.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.